Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Sarén

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Molecular Therapy Oncolytics|November 22, 2017
Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in NeurotoxicityTina Sarén, Mohanraj Ramachandran, Miika Martikainen, et al.
Science Immunology|January 31, 2025
Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domainsStefano Barbera, Matthijs J A Schuiling, Nathaniel A Sanjaya, et al.
Nanomaterials (Basel, Switzerland)|April 25, 2020
Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized LipodisksSara Lundsten, Víctor Agmo Hernández, Lars Gedda, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 27, 2022
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapyTherese Sjöholm, Alexander Korenyushkin, Gustav Gammelgård, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 19, 2023
Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapyTherese Sjöholm, Alexander Korenyushkin, Gustav Gammelgård, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomasJing Ma, Tina Sarén, Chuan Jin, et al.
Nature Communications|August 10, 2023
Complementarity-determining region clustering may cause CAR-T cell dysfunctionTina Sarén, Giulia Saronio, Paula Marti Torrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsTina Sarén, Mohanraj Ramachandran, Gustav Gammelgård, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Molecular Therapy Oncolytics|November 22, 2017
Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in NeurotoxicityTina Sarén, Mohanraj Ramachandran, Miika Martikainen, et al.
Science Immunology|January 31, 2025
Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domainsStefano Barbera, Matthijs J A Schuiling, Nathaniel A Sanjaya, et al.
Nanomaterials (Basel, Switzerland)|April 25, 2020
Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized LipodisksSara Lundsten, Víctor Agmo Hernández, Lars Gedda, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 27, 2022
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapyTherese Sjöholm, Alexander Korenyushkin, Gustav Gammelgård, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 19, 2023
Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapyTherese Sjöholm, Alexander Korenyushkin, Gustav Gammelgård, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomasJing Ma, Tina Sarén, Chuan Jin, et al.
Nature Communications|August 10, 2023
Complementarity-determining region clustering may cause CAR-T cell dysfunctionTina Sarén, Giulia Saronio, Paula Marti Torrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsTina Sarén, Mohanraj Ramachandran, Gustav Gammelgård, et al.
Pageof 1